The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA fall 2023 vaccines in the United States

References

• United Nations. UN News. WHO chief declares end to COVID-19 as a global health emergency, 2023. Available from: https://news.un.org/en/story/2023/05/1136367.
   Google Scholar
• Centers for Disease Control and Prevention. End of the Federal COVID-19 Public Health Emergency (PHE) Declaration [cited 2023 September 12]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/your-health/end-of-phe.html.
   Google Scholar
• Jones JM, Manrique IM, Stone MS, et al. Estimates of SARS-CoV-2 seroprevalence and incidence of primary SARS-CoV-2 infections among blood donors, by COVID-19 vaccination status - United States, April 2021-September 2022. MMWR Morb Mortal Wkly Rep. 2023;72(22):601–605. doi: 10.15585/mmwr.mm7222a3.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Updated (2023-2024 Formula). COVID-19 vaccine: interim 2023-2024 COVID-19 Immunization Schedule for Persons 6 Months of Age and Older. 2023. Available from: https://www.cdc.gov/vaccines/covid-19/downloads/COVID-19-immunization-schedule-ages-6months-older.pdf.
   Google Scholar
• Hodcroft E. CoVariants. Overview of variants in countries: France. 2023. Available from: https://covariants.org/.
   Google Scholar
• Rosenblum HG, Wallace M, Godfrey M, et al. Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines - United States, October 2022. MMWR Morb Mortal Wkly Rep. 2022;71(45):1436–1441. doi: 10.15585/mmwr.mm7145a2.
   PubMed Web of Science ®Google Scholar
• Link-Gelles R, Ciesla AA, Roper LE, et al. Early estimates of bivalent mRNA booster dose vaccine effectiveness in preventing symptomatic SARS-CoV-2 infection attributable to Omicron BA.5- and XBB/XBB.1.5-related sublineages among immunocompetent adults - increasing community access to testing program, United States. December 2022-January 2023. MMWR Morb Mortal Wkly Rep. 2023;72(5):119–124. doi: 10.15585/mmwr.mm7205e1.
   Google Scholar
• Link-Gelles R, Weber ZA, Reese SE, et al. Estimates of bivalent mRNA vaccine durability in preventing COVID-19-associated hospitalization and critical illness among adults with and without immunocompromising conditions - VISION Network, September 2022-April 2023. MMWR Morb Mortal Wkly Rep. 2023;72(21):579–588. doi: 10.15585/mmwr.mm7221a3.
   PubMedGoogle Scholar
• U.S. Food and Drug Administration. Recommendation for the 2023-2024 Formula of COVID-19 vaccines in the U.S. [cited 2023 June 16]. Available from: https://www.fda.gov/media/169591/download.
   Google Scholar
• Hodcroft E. CoVariants [cited 2023 January 23]. Available from: https://covariants.org/.
   Google Scholar
• Utami AM, Rendrayani F, Khoiry QA, et al. Economic evaluation of COVID-19 vaccination: a systematic review. J Glob Health. 2023;13:06001. doi: 10.7189/jogh.13.06001.
   PubMed Web of Science ®Google Scholar
• Kohli MA, Maschio M, Lee A, et al. The potential clinical impact of implementing different COVID-19 boosters in fall 2022 in the United States. J Med Econ. 2022;25(1):1127–1139. doi: 10.1080/13696998.2022.2126127.
   PubMed Web of Science ®Google Scholar
• Wang X, Haeussler K, Spellman A, et al. Comparative effectiveness of mRNA-1273 and BNT162b2 COVID-19 vaccines in immunocompromised individuals: a systematic review and meta-analysis using the GRADE framework. Front Immunol. 2023:14:1204831. doi: 10.3389/fimmu.2023.1204831.
   Google Scholar
• Nguyen VB, Boileau C, Bogdanov A, et al. Relative effectiveness of BNT162b2, mRNA-1273, and Ad26.COV2.S vaccines and homologous boosting in preventing COVID-19 in adults in the US. Open Forum Infect Dis. 2023;10(7):ofad288. doi: 10.1093/ofid/ofad288.
   Google Scholar
• Ono S, Michihata N, Yamana H, et al. Comparative effectiveness of BNT162b2 and mRNA-1273 booster dose after BNT162b2 primary vaccination against the Omicron variants: a retrospective cohort study using large-scale population-based registries in Japan. Clin Infect Dis. 2023;76(1):18–24. doi: 10.1093/cid/ciac763.
   PubMed Web of Science ®Google Scholar
• Mayr FT, Talisa VB, Shaikh OS, et al. Comparative COVID-19 vaccine effectiveness over time in veterans. Open Forum Infect Dis. 2022;9(7):ofac311. doi: 10.1093/ofid/ofac311.
   PubMed Web of Science ®Google Scholar
• Hulme WJ, Horne EMF, Parker EPK, et al. Comparative effectiveness of BNT162b2 versus mRNA-1273 covid-19 vaccine boosting in England: matched cohort study in OpenSAFELY-TPP. BMJ. 2023;380:e072808. doi: 10.1136/bmj-2022-072808.
   PubMedGoogle Scholar
• Kopel H, Nguyen VH, Boileau C, et al. Comparative Effectiveness of Bivalent (Original/Omicron BA.4/BA.5) COVID-19 Vaccines in Adults. Vaccines. 2023;11(11):1711. doi: 10.3390/vaccines11111711.
   Google Scholar
• Wolfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581(7809):465–469. doi: 10.1038/s41586-020-2196-x.
   PubMed Web of Science ®Google Scholar
• Imai N, Cori A, Dorigatti I, et al. Report 3: transmissibility of 2019-nCOV. Imperial College London. 2020 [updated January 25, 2020; cited 2022 May 15]. Available from: doi: 10.25561/77148.
   Google Scholar
• Moderna Inc. Moderna COVID-19 Variant Vaccines. Presentation to the Vaccines and Related Biological Products Advisory Committee. 2023 [cited 2023 June 23]. Available from: https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-june-15-2023-meeting-announcement#event-materials.
   Google Scholar
• Tseng HF, Ackerson BK, Sy LS, et al. mRNA-1273 bivalent (original and Omicron) COVID-19 vaccine effectiveness against COVID-19 outcomes in the United States. Nat Commun 2023;14:5851. doi: 10.1038/s41467-023-41537-7.
   Google Scholar
• Higdon MM, Baidya A, Walter KK, et al. Duration of effectiveness of vaccination against COVID-19 caused by the Omicron variant. Lancet Infect Dis. 2022;22(8):1114–1116. doi: 10.1016/S1473-3099(22)00409-1.
   PubMed Web of Science ®Google Scholar
• Pratama NR, Wafa IA, Budi DS, et al. Effectiveness of COVID-19 vaccines against SARS-CoV-2 Omicron variant (B.1.1.529): a systematic review with meta-analysis and meta-regression. Vaccines (Basel). 2022;10(12):2180. doi: 10.3390/vaccines10122180.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Weekly flu vaccination dashboard: influenza vaccination coverage, adults. 2023 [cited 2023 May 5]. Available from: https://www.cdc.gov/flu/fluvaxview/dashboard/vaccination-adult-coverage.html.
   Google Scholar
• Shang W, Kang L, Cao G, et al. Percentage of asymptomatic infections among SARS-CoV-2 Omicron variant-positive individuals: a systematic review and meta-analysis. Vaccines (Basel). 2022;10(7):1049. doi: 10.3390/vaccines10071049.
   PubMed Web of Science ®Google Scholar
• US Bureau of Labor Statistics. US Consumer Price Index: medical care in US city average, all urban consumers. 2023 [cited 2023 May 15]. Available from: https://data.bls.gov/cgi-bin/surveymost.
   Google Scholar
• Koumpias AM, Schwartzman D, Fleming O. Long-haul COVID: healthcare utilization and medical expenditures 6 months post-diagnosis. BMC Health Serv Res. 2022;22(1):1010. doi: 10.1186/s12913-022-08387-3.
   PubMed Web of Science ®Google Scholar
• Saydah S. Update: epidemiologic characteristics of long COVID. ACIP Meeting Slides. Atlanta, GA: Centers for Disease Control and Prevention; 2023 [cited 2023 September 12]. Available from: https://www.cdc.gov/vaccines/acip/meetings/slides-2023-09-12.html.
   Google Scholar
• Centers for Disease Control and Prevention. National Center for Health Statistics. National Vital Statistics System - Life Expectancy 2017 [cited 2020 June 24]. Available from: https://ftp.cdc.gov/pub/Health_Statistics/NCHS/Publications/NVSR/68_07/.
   Google Scholar
• Hanmer J, Lawrence WF, Anderson JP, et al. Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med Decis Making. 2006;26(4):391–400. doi: 10.1177/0272989X06290497.
   PubMed Web of Science ®Google Scholar
• Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093–1103. doi: 10.1001/jama.2016.12195.
   PubMed Web of Science ®Google Scholar
• IBM Micromedex. Average wholesale price from RedBook NDC accessed via Compendia [cited 2023 August 16]. Available from: Available from: https://www.ibm.com/us-en/marketplace/micromedex-red-book.
   Google Scholar
• Wolters Kluwer. Medi-Span Prescription Drug Pricing Data. 2023. Available from: https://www.wolterskluwer.com/en/solutions/medi-span/medi-span/drug-pricing-data.
   Google Scholar
• Centers for Medicare and Medicaid Services. National Physician Fee Schedule Relative Value File April Release. 2023 [cited 2023 May 3]. Available from: https://www.cms.gov/medicare/medicare-fee-service-payment/physicianfeesched/pfs-relative-value-files/rvu23b.
   Google Scholar
• IQVIA Institute Report. Trends in Vaccine Administration in the United States. 2023 [cited 2023 August 7]. Available from: https://www.iqvia.com/insights/the-iqvia-institute/reports/trends-in-vaccine-administration-in-the-united-states.
   Google Scholar
• Briggs AH, Sculpher MJ, Claxton K. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.
   Google Scholar
• Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness–the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796–797. doi: 10.1056/NEJMp1405158.
   PubMed Web of Science ®Google Scholar
• Thornburg NJ. Update on current epidemiology of COVID-19 pandemic and SARS-CoV-2 variants. Presentation to the Vaccines and Related Biological Products Advisory Committee. Available from: https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-june-15-2023-meeting-announcement#event-materials.
   Google Scholar
• Reese H, Iuliano AD, Patel NN, et al. Estimated incidence of coronavirus disease 2019 (COVID-19) illness and hospitalization-United States, February-September 2020. Clin Infect Dis. 2021;72(12):e1010–e1017. doi: 10.1093/cid/ciaa1780.
   PubMed Web of Science ®Google Scholar
• Wang L, Berger N, Kaelber D, et al. COVID infection rates, clinical outcomes, and racial/ethnic and gender disparities before and after Omicron emerged in the US. medRxiv. 2022; 2022.02.21.22271300. doi: 10.1101/2022.02.21.22271300.
   Google Scholar
• Sandmann FG, Tessier E, Lacy J, et al. Long-term health-related quality of life in non-hospitalized coronavirus disease 2019 (COVID-19) cases with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in England: longitudinal analysis and cross-sectional comparison with controls. Clin Infect Dis. 2022;75(1):e962–e973. doi: 10.1093/cid/ciac151.
   PubMedGoogle Scholar
• The PHOSP-COVID Collaborative Group. Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. Lancet Respir Med. 2022;10(8):761–775. doi: 10.1016/S2213-2600(22)00127-8.
   PubMed Web of Science ®Google Scholar
• Bowe B, Xie Y, Al-Aly Z. Postacute sequelae of COVID-19 at 2 years. Nat Med. 2023;29(9):2347–2357. doi: 10.1038/s41591-023-02521-2.
   PubMed Web of Science ®Google Scholar
• Zhang V, Fisher M, Hou W, et al. Incidence of new-onset hypertension post-COVID-19: comparison with influenza. Hypertension. 2023;80(10):2135–2148. doi: 10.1161/HYPERTENSIONAHA.123.21174.
   PubMed Web of Science ®Google Scholar
• Hoeg TB, Ladhani S, Prasad V. How methodological pitfalls have created widespread misunderstanding about long COVID. BMJ Evid Based Med. 2023;:bmjebm-2023-112338. doi: 10.1136/bmjebm-2023-112338.
   Google Scholar
• Ford ND, Slaughter D, Edwards D, et al. Long COVID and significant activity limitation among adults, by age - United States, June 1-13, 2022, to June 7-19, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(32):866–870. doi: 10.15585/mmwr.mm7232a3.
   PubMed Web of Science ®Google Scholar
• Postma M, Biundo E, Chicoye A, et al. Capturing the value of vaccination within health technology assessment and health economics: country analysis and priority value concepts. Vaccine. 2022;40(30):3999–4007. doi: 10.1016/j.vaccine.2022.04.026.
   PubMed Web of Science ®Google Scholar
• Lakdawalla DN, Doshi JA, Garrison LP, Jr., et al. Defining elements of value in health care - a health economics approach: an ISPOR Special Task Force Report [3]. Value Health. 2018;21(2):131–139. doi: 10.1016/j.jval.2017.12.007.
   PubMed Web of Science ®Google Scholar
• Di Fusco M, Mendes D, Steuten L, et al. The societal value of vaccines: expert-based conceptual framework and methods using COVID-19 vaccines as a case study. Vaccines (Basel). 2023;11(2):234. doi: 10.3390/vaccines11020234.
   PubMed Web of Science ®Google Scholar
• Boehmer TK, Kompaniyets L, Lavery AM, et al. Association between COVID-19 and myocarditis using hospital-based administrative data - United States, March 2020-January 2021. MMWR Morb Mortal Wkly Rep. 2021;70(35):1228–1232. doi: 10.15585/mmwr.mm7035e5.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Estimated flu-related illnesses, medical visits, hospitalizations, and deaths in the United States—2019–2020 flu season. 2022 [cited 2022 October 28]. Available from: https://www.cdc.gov/flu/about/burden/2019-2020.html.
   Google Scholar
• Di Fusco M, Shea KM, Lin J, et al. Health outcomes and economic burden of hospitalized COVID-19 patients in the United States. J Med Econ. 2021;24(1):308–317. doi: 10.1080/13696998.2021.1886109.
   PubMed Web of Science ®Google Scholar
• Verna EC, Landis C, Brown RS, et al. Factors associated with readmission in the United States following hospitalization with coronavirus disease 2019. Clin Infect Dis. 2022;74(10):1713–1721. doi: 10.1093/cid/ciab464.
   PubMed Web of Science ®Google Scholar
• Chopra V, Flanders SA, O'Malley M, et al. Sixty-day outcomes among patients hospitalized with COVID-19. Ann Intern Med. 2021;174(4):576–578. doi: 10.7326/M20-5661.
   PubMed Web of Science ®Google Scholar
• HCUPnet - Hospital Inpatient National Statistics. 2018 National Diagnoses - Clinical Classification Software Refined (CCSR), Principal Diagnosis: CIR005 Myocarditis and Cardiomyopathy. 2018 [cited 2021 October 13]. Available from: https://hcupnet.ahrq.gov/#setup.
   Google Scholar
• Centers for Medicare and Medicaid Services. 2022 National Physician Fee Schedule Relative Value File October Release. 2022 [cited 2023 May]. Available from: https://www.cms.gov/medicare/medicare-fee-for-service-payment/physicianfeesched/pfs-relative-value-files.
   Google Scholar
• Fiedler M, Song Z. Brookings report: estimating potential spending on COVID-19 care [cited 2020 July 22]. Available from: https://www.brookings.edu/research/estimating-potential-spending-on-covid-19-care/.
   Google Scholar
• Huang BZ, Creekmur B, Yoo MS, et al. Healthcare utilization among patients diagnosed with COVID-19 in a large integrated health system. J Gen Intern Med. 2022;37(4):830–837. doi: 10.1007/s11606-021-07139-z.
   PubMed Web of Science ®Google Scholar
• Prosser LA, Harpaz R, Rose AM, et al. A cost-effectiveness analysis of vaccination for prevention of herpes zoster and related complications: input for national recommendations. Ann Intern Med. 2019;170(6):380–388. doi: 10.7326/M18-2347.
   PubMed Web of Science ®Google Scholar
• Smith KJ, Roberts MS. Cost-effectiveness of newer treatment strategies for influenza. Am J Med. 2002;113(4):300–307. doi: 10.1016/s0002-9343(02)01222-6.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Isolation and precautions for people with COVID-19 [cited 2022 Dec 21]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/your-health/isolation.html.
   Google Scholar
• Barbut F, Galperine T, Vanhems P, et al. Quality of life and utility decrement associated with Clostridium difficile infection in a French hospital setting. Health Qual Life Outcomes. 2019;17(1):6. doi: 10.1186/s12955-019-1081-5.
   PubMedGoogle Scholar